\u307f\u306a\u3055\u3093\u3001\u3053\u3093\u306b\u3061\u306f\uff01\u30a4\u30f3\u30b9\u30c8\u30e9\u30af\u30bf\u30fc\u306eNaoko\u3067\u3059\u3002<\/p>\n
\u524d\u56de\u306f\u3001demic\u300c\u4eba\u53e3\u306e\u3001\u4eba\u3005\u306e\u300d\u304c\u3064\u304f\u8a9e\u3092\u5b66\u3073\u307e\u3057\u305f\u3002<\/p>\n
\u539a\u751f\u52b4\u50cd\u7701\u304c\u30b3\u30ed\u30ca\u306e\u65b0\u85ac\u3068\u3057\u3066\u30a2\u30b9\u30c8\u30e9\u30bc\u30cd\u30ab\u793e\u306e\u300c\u30a8\u30d0\u30b7\u30a7\u30eb\u30c9\u300d\u3092\u7279\u4f8b\u627f\u8a8d\u3057\u307e\u3057\u305f\u3002\u300c\u30a8\u30d0\u30b7\u30a7\u30eb\u30c9\u300d\u306f\u300c\u6cbb\u7642\u300d\u3060\u3051\u3067\u306f\u306a\u304f\u3001\u300c\u4e88\u9632\u300d\u306b\u3082\u52b9\u679c\u304c\u3042\u308b\u306e\u3067\u3059\u306d\u3002<\/p>\n
\u30a2\u30b9\u30c8\u30e9\u30bc\u30cd\u30ab\u3067\u306f\u65e5\u672c\u3067\u3053\u306e\u85ac\u304c\u627f\u8a8d\u3055\u308c\u305f\u3053\u3068\u3092\u3069\u306e\u3088\u3046\u306b\u7d39\u4ecb\u3057\u3066\u3044\u308b\u304b\u3001\u30a6\u30a7\u30d6\u30da\u30fc\u30b8\u3092\u898b\u3066\u307f\u307e\u3057\u3087\u3046\u3002<\/p>\n
First global approval for Evusheld as a COVID-19 treatment<\/p>\n
\u30b9\u30e9\u30c3\u30b7\u30e5\u3067\u533a\u5207\u308b\u3068\u2193<\/p>\n
First global approval\/ for Evusheld\/ as a COVID-19 treatment
\n\u4e16\u754c\u521d\u306e\u627f\u8a8d\/ Evusheld\u306e(\u306b\u3068\u3063\u3066)\/COVID-19\u6cbb\u7642\u85ac\u3068\u3057\u3066<\/p>\n
\u65e5\u672c\u3067\u306e\u627f\u8a8d\u304c\u4e16\u754c\u521d\u306a\u306e\u3067\u3059\u306d\u3002
\n\u3082\u3063\u3068\u8a73\u3057\u3044\u6587\u3082\u898b\u3066\u307f\u307e\u3057\u3087\u3046\u3002<\/p>\n
AstraZeneca’s Evusheld\/ (tixagevimab and cilgavimab, formerly AZD7442)\/, a long-acting antibody combination,\/ has been approved\/ in Japan\/ for both prevention (pre-exposure prophylaxis) and treatment\/ of symptomatic disease\/ caused by SARS-CoV-2 infection. \/The decision marks\/ the first global marketing approval\/ for Evusheld\/ as a treatment for COVID-19.<\/p>\n
\u3042\u3089\u304b\u3058\u3081\u30b9\u30e9\u30c3\u30b7\u30e5\u3092\u5165\u308c\u307e\u3057\u305f\u3002<\/p>\n
\u533b\u7642\u95a2\u4fc2\u306e\u5358\u8a9e\u306b\u99b4\u67d3\u3093\u3067\u3044\u308b\u65b9\u306b\u306f\u3055\u307b\u3069\u96e3\u3057\u3044\u5358\u8a9e\u306f\u306a\u3044\u3068\u601d\u3044\u307e\u3059\u304c\u3001\u4e00\u90e8\u548c\u8a33\u3092\u8f09\u305b\u3066\u304a\u304d\u307e\u3059\u306d\u3002<\/p>\n
antibody combination\u3000\u6297\u4f53\u30ab\u30af\u30c6\u30eb\uff08\u7642\u6cd5\uff09
\nfor both prevention and treatment \u4e88\u9632\u304a\u3088\u3073\u6cbb\u7642\u3068\u3057\u3066
\nsymptomatic disease\u3000\u75c7\u5019\u6027\u75be\u60a3<\/p>\n
\u672c\u65e5\u306e\u82f1\u6587\u3092\u5fdc\u7528\u3057\u3066\u300c\u30a8\u30d0\u30b7\u30a7\u30eb\u30c9\u300d\u3068\u306f\uff1f\u3092\u82f1\u8a9e\u3067\u8aac\u660e\u3067\u304d\u307e\u3059\u3002<\/p>\n
\u4f8b\u6587
\nEvusheld is a long-acting antibody combination approved in Japan for preventing and treating symptomatic disease caused by SARS-CoV-2 infection.<\/p>\n","protected":false},"excerpt":{"rendered":"
\u307f\u306a\u3055\u3093\u3001\u3053\u3093\u306b\u3061\u306f\uff01\u30a4\u30f3\u30b9\u30c8\u30e9\u30af\u30bf\u30fc\u306eNaoko\u3067\u3059\u3002 \u304a\u3055\u3089\u3044\u3000\uff5edemic \u524d\u56de\u306f\u3001demic\u300c\u4eba\u53e3\u306e\u3001\u4eba\u3005\u306e\u300d\u304c\u3064\u304f\u8a9e\u3092\u5b66\u3073\u307e\u3057\u305f\u3002 \u65b0\u85ac\u300c\u30a8\u30d0\u30b7\u30a7\u30eb\u30c9\u300d \u539a\u751f\u52b4\u50cd\u7701\u304c\u30b3\u30ed\u30ca\u306e\u65b0\u85ac\u3068\u3057\u3066\u30a2\u30b9\u30c8\u30e9\u30bc\u30cd\u30ab\u793e\u306e\u300c\u30a8\u30d0\u30b7\u30a7\u30eb\u30c9\u300d\u3092\u7279\u4f8b\u627f\u8a8d\u3057\u307e\u3057\u305f\u3002\u300c\u30a8\u30d0\u30b7\u30a7\u30eb\u30c9\u300d\u306f\u300c\u6cbb\u7642\u300d\u3060\u3051\u3067\u306f\u306a\u304f\u3001\u300c\u4e88\u9632\u300d\u306b\u3082\u52b9\u679c\u304c\u3042\u308b\u306e\u3067\u3059\u306d\u3002 \u30a2\u30b9\u30c8\u30e9\u30bc\u30cd\u30ab\u793e\u306e\u5831\u9053 \u30a2\u30b9\u30c8\u30e9\u30bc\u30cd\u30ab\u3067\u306f\u65e5\u672c\u3067\u3053\u306e\u85ac\u304c\u627f\u8a8d\u3055\u308c\u305f\u3053\u3068\u3092\u3069\u306e\u3088…<\/p>\n","protected":false},"author":62,"featured_media":16510,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[441,5],"tags":[860,22],"class_list":{"0":"post-16447","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-word","8":"category-learning","9":"tag-860","10":"tag-22","11":"article cf"},"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/www.fruitfulenglish.com\/blog\/wp-json\/wp\/v2\/posts\/16447","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fruitfulenglish.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fruitfulenglish.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fruitfulenglish.com\/blog\/wp-json\/wp\/v2\/users\/62"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fruitfulenglish.com\/blog\/wp-json\/wp\/v2\/comments?post=16447"}],"version-history":[{"count":1,"href":"https:\/\/www.fruitfulenglish.com\/blog\/wp-json\/wp\/v2\/posts\/16447\/revisions"}],"predecessor-version":[{"id":16448,"href":"https:\/\/www.fruitfulenglish.com\/blog\/wp-json\/wp\/v2\/posts\/16447\/revisions\/16448"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fruitfulenglish.com\/blog\/wp-json\/wp\/v2\/media\/16510"}],"wp:attachment":[{"href":"https:\/\/www.fruitfulenglish.com\/blog\/wp-json\/wp\/v2\/media?parent=16447"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fruitfulenglish.com\/blog\/wp-json\/wp\/v2\/categories?post=16447"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fruitfulenglish.com\/blog\/wp-json\/wp\/v2\/tags?post=16447"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}